| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04227938 Details | 2023-08-28 Interventional | 1 | 1 | ALPN-101 Graft vs Host D… Graft Vs Host D… | Change in sponsor strategy - | |||
| NCT02122185 Details | 2023-08-28 Interventional | 2 | - | Metformin Adenocarcinoma Ascites Brenner Tumor Carcinoma Carcinoma, Endo… Carcinoma, Ovar… Cystadenocarcin… Cystadenocarcin… Fallopian Tube … Germinoma Neoplasms, Germ… Ovarian Neoplas… Peritoneal Neop… Pleural Effusio… Pleural Effusio… Recurrence Malignant Ascit… Malignant Pleur… Ovarian Clear C… Ovarian Endomet… Ovarian Mixed E… Ovarian Serous … Ovarian Undiffe… Recurrent Fallo… Recurrent Ovari… Recurrent Ovari… Recurrent Prima… Stage IIIA Fall… Stage IIIA Ovar… Stage IIIA Ovar… Stage IIIA Prim… Stage IIIB Fall… Stage IIIB Ovar… Stage IIIB Ovar… Stage IIIB Prim… Stage IIIC Fall… Stage IIIC Ovar… Stage IIIC Ovar… Stage IIIC Prim… Stage IV Fallop… Stage IV Ovaria… Stage IV Ovaria… Stage IV Primar… | Enrollment halted for planned interim analysis. - | |||
| NCT05935774 Details | 2023-08-25 Interventional | 2 | 0 | Atezolizumab Trabedersen Carcinoma Carcinoma, Non-… Lung Neoplasms Metastatic Lung… Recurrent Lung … Stage IV Lung C… | Withdrawn prior to opening to accrual. - | |||
| NCT05926440 Details | 2023-08-25 Interventional | 3 | 0 | Somatomedin B Vaccines COVID-19 | we has selected a new candidate vaccine which is monovalent. - | |||
| NCT05276830 Details | 2023-08-25 Interventional | 2 | 5 | Dexmedetomidine Dementia Psychomotor Agi… Agitation | Study was terminated for business reasons; not due to safety or efficacy concerns The study was terminated prematurely due to business reasons. There were no Safety or Efficacy Concerns. | |||
| NCT03139370 2020-005456-37 Details | 2023-08-25 Interventional | 1 | 16 | Cyclophosphamid… Fludarabine Solid Tumor | The study was terminated due to the sponsor's decision to discontinue the clinical trial. - | |||
| NCT02740920 Details | 2023-08-25 Interventional | 2 | 9 | Pembrolizumab Melanoma Metastatic Mela… | - - | |||
| NCT05567770 Details | 2023-08-24 Interventional | 1 | 0 | Androgens Prostatic Neopl… Prostate Cancer… | Stakeholder elected not to proceed with the study - | |||
| NCT03606174 Details | 2023-08-24 Interventional | 2 | 260 | Nivolumab Pembrolizumab Carcinoma Carcinoma, Tran… Urinary Bladder… Urothelial Carc… Urothelial Carc… Urothelial Carc… Urothelial Carc… Urothelial Carc… | The study was terminated due to sponsor decision / portfolio prioritization, and not due to
safety reasons. - | |||
| NCT03450707 Details | 2023-08-24 Interventional | 2 | 93 | Thiamine Heart Arrest Cardiac Arrest | DSMB recommendation based on differing mortality in a subgroup analysis The study was stopped early by the Data Safety and Monitoring Board (DSMB) due to a signal of increased mortality in the thiamine group with a lactate > 5 | |||
| NCT04299438 Details | 2023-08-23 Interventional | 3 | 164 | Propranolol Pregnancy, Prol… | Stopped at interim analysis - | |||
| NCT03736629 Details | 2023-08-23 Interventional | 2 | [1 Refs] | 17 | Azithromycin Asthma Asthma Chronic | Inability to accrue patients, particularly after COVID pandemic. Early termination leading to small numbers of subjects analyzed. | ||
| NCT01618357 Details | 2023-08-23 Interventional | 1 | - | Veliparib Breast Neoplasm… Breast Cancer | final subject consented to dose level 4 - | |||
| NCT00662740 2007-005134-36 Details | 2023-08-23 Interventional | 3 | 220 | Salmeterol Xina… Tiotropium Brom… Lung Diseases Pulmonary Disea… | - - | |||
| NCT03695250 Details | 2023-08-22 Interventional | 1/2 | 8 | Linrodostat Nivolumab Carcinoma Carcinoma, Hepa… Metastatic Hepa… Stage III Hepat… Stage IIIA Hepa… Stage IIIB Hepa… Stage IV Hepato… Stage IVA Hepat… Stage IVB Hepat… Unresectable He… | Funding source decision to terminate study. - | |||
| NCT03329378 Details | 2023-08-22 Interventional | 2 | 7 | Albumin-Bound P… Carboplatin Cyclophosphamid… Docetaxel Doxorubicin Paclitaxel Pertuzumab Trastuzumab Breast Neoplasm… Locally Advance… | Data Safety Monitoring Board is in agreement with the study findings so far and the stopping
rule has been met, which suspends the study treatment arms in March 2021. - | |||
| NCT02906332 Details | 2023-08-22 Interventional | 2 | 12 | Dexamethasone Lenalidomide Pembrolizumab Multiple Myelom… Neoplasms, Plas… | FDA Hold Due to Updated Risks - | |||
| NCT00489710 Details | 2023-08-22 Interventional | 2 | 0 | Enzyme Inhibito… Immunomodulatin… Carcinoma, Rena… Kidney Neoplasm… Kidney Cancer | safety reasons - | |||
| NCT04886986 Details | 2023-08-21 Interventional | 1/2 | - | Gallium 68 PSMA… Prostatic Neopl… Prostate Cancer | Need to wait until a new collaborator is available and confirmed - | |||
| NCT04802837 Details | 2023-08-21 Interventional | 3 | 2 | Ridinilazole Vancomycin Clostridium Inf… Communicable Di… Infections Clostridioides … | SMT19969-C006 study was terminated in alignment with corporate decision to pursue further
development of drug candidate with a partner. - |